EN DE
Watch Citius Oncology, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Citius Oncology, Inc. (CTOR) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Citius Oncology, Inc. stock $0.46, price $0.56, that is 18.9% below the price, quality 21 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CO Citius Oncology, Inc. logo Thin data Nov 10, 2026

Citius Oncology, Inc.

CTOR · US
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Fair value $0.4564 · Overvalued
Quality 21/100
Negative free cash flow
Trails peers (0/6)
Narrow moat 5/100
Thin data
Estimate
Watch Citius Oncology, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$40.50 $0.4930 Fair Value $0.4564 Aug 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

27‑month range $0.4930 – $40.50 · fair‑value band $0.3423 – $0.5705 · the $0.5627 price screens above the $0.4564 fair value. As of Nov 10, 2026.

Follow Citius Oncology in your weekly email

Every Wednesday you see whether Citius Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.

Show moreShow less

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey.

Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Stock analysis

Citius Oncology, Inc. (CTOR) currently trades at $0.5627, while our estimate is $0.4564, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3423 (bear) to $0.5705 (bull), the price of $0.5627 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Citius Oncology, Inc. reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$24.8M in FY2025.

Key figures

Market cap $60.7M Micro · P/S ratio 8.14 · EPS (TTM) $−0.4700 · Return on equity −127% · Return on assets (EBIT) −24.0% (4-year average) · Operating margin −596% · Revenue (TTM) $7.1M · Free cash flow −$5.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −19%, CTOR screens cheaper than that median.

Fair Value

Bear $0.3423 Fair Value $0.4564 Bull $0.5705
Price $0.5627 · Downside -18.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 32
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 7
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CTOR screens overvalued: fair value 19% below the price. Compare with Merck KGaA →

Compare Citius Oncology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside −18.9% · Below median
Profitability
Return on assets −24.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.35× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 8.54× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs CTOR
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs CTOR
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs CTOR
Haleon plc HLN $9.06 $8.62 −5% vs CTOR
Merck KGaA MRK €149.35 €109.18 −27% vs CTOR
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs CTOR
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs CTOR
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs CTOR
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs CTOR
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs CTOR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Citius Oncology, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Citius Oncology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CTOR

Frequently asked questions

Is Citius Oncology, Inc. (CTOR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.4564 versus a price of $0.5627, about 19% lower (overvalued).
What is the fair value of CTOR?
Our estimate for Citius Oncology, Inc. is $0.4564 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.5627.
What is the quality score of CTOR?
Citius Oncology, Inc. has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Citius Oncology, Inc. (CTOR)?
Our calculated price target is the estimate of $0.4564 (as of Nov 10, 2026). Cautious scenario $0.3423, optimistic scenario $0.5705. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Citius Oncology, Inc. stock forecast for 2026?
Our estimate puts fair value at $0.4564, about 19% lower versus a price of $0.5627 (overvalued). Cautious scenario $0.3423, optimistic scenario $0.5705. The calculation is refreshed regularly with new filings.
What is the revenue of Citius Oncology, Inc. (CTOR)?
Citius Oncology, Inc. reported trailing-twelve-month revenue of about $7.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Citius Oncology, Inc. (CTOR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Citius Oncology, Inc. it is $0.4564 per share (as of Nov 10, 2026), against a price of $0.5627.
Is Citius Oncology, Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CTOR trades above its calculated fair value: price $0.5627, fair value $0.4564, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTOR?
No. The price is what the market pays today ($0.5627); the fair value is what the company's own numbers justify ($0.4564). For Citius Oncology, Inc. the two are $0.1063 per share apart. That gap is exactly why we show both numbers side by side.
How much is Citius Oncology, Inc. worth?
The market values Citius Oncology, Inc. at about $60.7M (market capitalisation, as of Nov 10, 2026). Per share that is $0.5627; our models calculate a fair value of $0.4564 per share.
What do the bullish and bearish scenarios say about CTOR?
Our models span a range for Citius Oncology, Inc.: cautious scenario $0.3423, base $0.4564, optimistic $0.5705 per share (as of Nov 10, 2026, price $0.5627). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Citius Oncology, Inc. (CTOR)?
Balance-sheet figures for Citius Oncology, Inc. (as of Nov 10, 2026): return on equity −126.6%. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is CTOR from its 52-week high?
Citius Oncology, Inc. trades at $0.5627, about 66% below its 52-week high of $1.64 and 14% above the low of $0.4930 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4564 is for.
Which stocks are comparable to Citius Oncology, Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Citius Oncology, Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $0.5627, calculated fair value $0.4564 (−19%), Quality Score 21/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Citius Oncology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Citius Oncology, Inc. (CTOR)?
The closing price on Nov 10, 2026 was $0.5627. Our estimate is $0.4564, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Citius Oncology, Inc. right now?
Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Citius Oncology, Inc.

How large is the market capitalisation of Citius Oncology, Inc. (CTOR)?
The market capitalisation of Citius Oncology, Inc. is $60.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Citius Oncology, Inc. (CTOR)?
The price-to-sales ratio of Citius Oncology, Inc. is 8.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Citius Oncology, Inc. (CTOR)?
Earnings per share at Citius Oncology, Inc. are $−0.4700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Citius Oncology, Inc. (CTOR)?
The return on equity (ROE) of Citius Oncology, Inc. is −127% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Citius Oncology, Inc. (CTOR)?
On an EBIT basis the return on assets of Citius Oncology, Inc. is −24.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Citius Oncology, Inc. (CTOR)?
The operating margin of Citius Oncology, Inc. is −596% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Citius Oncology, Inc. (CTOR) generate?
The free cash flow of Citius Oncology, Inc. is −$5.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Citius Oncology, Inc. (CTOR) hold?
Citius Oncology, Inc. holds more cash than debt, $125K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Citius Oncology, Inc. in the live analysis

One click puts Citius Oncology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.